ReviewDrug design, development and therapy2026
Swarm Intelligence in Drug Discovery Applications: Unlocking Deeper Insights on the Identification and Optimization of Potential Drug Candidates.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Swarm-based analysis technology represents a class of computational approaches inspired by biological systems, such as bees or ants, to solve complex and high-dimensional problems through the collective behavior of interacting agents. This review provides an overview of swarm intelligence methods in drug discovery, covering foundational concepts, major algorithms, and representative applications in molecular docking, drug screening, de novo molecular design, and combinatorial chemical space exploration. We summarize classical swarm-based approaches and discuss recent hybrid frameworks integrating swarm intelligence with machine learning, deep learning, and large language model (LLM)-based multi-agent systems. In addition to highlighting their potential for adaptive search and multi-objective optimization, we critically examine current limitations, including scalability, convergence reliability, parameter sensitivity, and computational cost in high-dimensional biomedical settings. We further emphasize that many emerging frameworks, particularly LLM-enhanced and multi-agent swarm systems, remain at an early stage and have not yet been extensively validated in real-world drug discovery pipelines. Overall, swarm-based methods provide flexible and interpretable strategies for complex optimization tasks, while continued advances in data integration, benchmarking, and biologically informed modeling will be important for their broader application in drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.